In the News - 340B Matters
page-template,page-template-blog-large-image,page-template-blog-large-image-php,page,page-id-15484,ajax_fade,page_not_loaded,,qode-title-hidden,qode-theme-ver-9.1.3,wpb-js-composer js-comp-ver-4.11.1,vc_responsive

340B in the News

13 Jun STAT: Pursuit of profits is driving drug companies to break the 340B law

"Seventeen drug companies, including some of the world’s largest, are flouting a 30-year-old federal program that supports hospitals serving patients with low incomes and those who live in rural communities. Both the Trump and Biden administrations have deemed these actions unlawful. But these drugmakers continue to ignore the law,...

Read More

14 Mar Townhall: Drug Pricing Program Needs Protection

"President Biden’s call during his State of the Union address for Congress to pass legislation to control drug prices provides a good opportunity to note a law that already is on the books that helps curb drugmakers’ price hikes. As lawmakers prepare to debate the...

Read More

10 Jul 340B may curb high drug prices, new JAMA study finds

The 340B drug pricing program may discourage drug manufacturers from raising prices and instead may have the effect of reducing list prices for certain drugs. That’s according to a new study published in the Journal of the American Medical Association (JAMA). Study authors Sean Dickson of West Health and Ian...

Read More

20 Jun Townhall: Big Pharma Points Fingers While Leaders Fight for Lower Prices

"At a recent hearing of the Senate Finance Committee, Chairman Sen. Chuck Grassley (R-Iowa) warned the seven assembled drug company executives not to point fingers: “It’s time for solutions,” he said. They didn’t listen. Instead, they blamed everything from pharmacy benefit managers to Medicaid to the...

Read More

Want To Stay Up-To-Date On The Latest 340B News?